CIN: L24111UP1992PLC014240 Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, Website- <u>www.raymedlab.com</u> E-mail- <u>raymedlabs@rediffmail.com</u>, Phone no. - 0120-2426900, 9412700300

Date: 04.11.2023

To, The Head- Listing Compliance **BSE Limited,** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001

Scrip Code: 531207

Sub: <u>Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today i.e. **Saturday**, **November 04, 2023** (commenced at <u>12:00</u> Noon and concluded at <u>01:15</u> P.M.) at the Registered office of the company at 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304 has inter alia approved and passed the following resolutions:

- 1. The Board considered and took on record, the undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, for the quarter ended September 30, 2023. (Copy Enclosed).
- 2. Taking note of Certificate of Non-Applicability of Disclosure of Related Party Transactions on a consolidated basis as required under Regulation 23(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for half year ended on September 30, 2023.(Copy Enclosed)
- **3.** Took note of Closure of Trading Window for Designated Persons as required under SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 for the quarter ended September 30, 2023.
- **4.** Took note of Certificate of Non Applicability of Compliance with Report on Corporate Governance as required under Regulation 27(2) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter ended September 30, 2023.
- **5.** Took note of Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended September 30, 2023.

CIN: L24111UP1992PLC014240 Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, Website- <u>www.raymedlab.com</u> E-mail- <u>raymedlabs@rediffmail.com</u>, Phone no. - 0120-2426900, 9412700300

- **6.** Took note of The Reconciliation of Share Capital Audit Report Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2023.
- 7. Took note of Shareholding pattern pursuant to Regulation 31 of the (Listing Obligations and Disclosure Requirements) Regulation 2015 for the quarter ended September 30, 2023.
- **8.** Took note of Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2023.
- **9.** Taking note of Compliance Certificate on Structural Digital Database under SEBI (Prohibition of Insider Trading) Regulations, 2015 for the quarter ended September 30, 2023.

Kindly take the above information on your records.

Thanking you, Yours Sincerely, For Raymed Labs Limited

(Ajai Goyal) Whole Time Director DIN: 02636418

Place: Noida

CIN: L24111UP1992PLC014240 Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, Website- <u>www.raymedlab.com</u> E-mail- <u>raymedlabs@rediffmail.com</u>, Phone no. - 0120-2426900, 9412700300

Date: 04.11.2023

To, The Head- Listing Compliance **BSE Limited,** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001

Scrip Code: 531207

Subject: Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter ended September 30, 2023

Dear Sir/Madam,

With reference to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the disclosure of Statement of Deviation(s) or Variation(s) under the said regulation is not applicable to the Company.

We request you to kindly take the above information on your records.

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418

Place: Noida

CIN: L24111UP1992PLC014240 Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, Website- <u>www.raymedlab.com</u> E-mail- <u>raymedlabs@rediffmail.com</u>, Phone no. - 0120-2426900, 9412700300

Date: 04.11.2023

To, The Head- Listing Compliance **BSE Limited,** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001

Scrip Code: 531207

Subject: Non Applicability of Disclosure on Related Party Transactions on a consolidated basis under Regulation 23(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the half year ended September 30, 2023

Dear Sir,

This has reference to Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, where a company is exempt from compliance with few specified regulations if the listed entity is having paid up equity share capital not exceeding Rs. 10,00,00,000/- (Rupees Ten Crore) and net worth not exceeding Rs. 25,00,00,000/- (Rupees Twenty Five Crores) as on the last date of previous financial year.

Please note that our Company has Paid up Capital of Rs. **427.35 Lakhs** only (i.e. less than stipulated limit of Rs.10 Crore) and Net Worth of Rs. **(230.59) Lakhs** (i.e. less than stipulated limit of Rs. 25 Crore) as per the last audited balance sheet as on March 31, 2023.

Therefore, in terms of the aforesaid Regulation *i.e.* Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015, the Company is not under any obligation to file **Disclosure on Related Party Transactions on a consolidated basis** for the half year ended on September 30, 2023.

We request you to kindly take the above information on your records.

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418

Place: Noida